
Heron Therapeutics reports fourth-quarter, full-year 2023 financial results
Heron Therapeutics reported its fourth-quarter and full-year 2023 financial results, achieving a quarterly record of $5.6 million in net product sales from Zynrelef. The company also reported $107.9 million in revenue from its oncology care franchise. CEO Craig Collard expressed optimism for the company’s long-term success and profitability, attributing positive momentum to strategic decisions made…